title: Imatinib plasma levels: correlation with clinical benefit in GIST patients.
authors.forename: N
authors.initials: N
authors.lastname: Widmer
authors.forename: L A
authors.initials: LA
authors.lastname: Decosterd
authors.forename: C
authors.initials: C
authors.lastname: Csajka
authors.forename: M
authors.initials: M
authors.lastname: Montemurro
authors.forename: A
authors.initials: A
authors.lastname: Haouala
authors.forename: S
authors.initials: S
authors.lastname: Leyvraz
authors.forename: T
authors.initials: T
authors.lastname: Buclin
mesh_terms: D000418:Albumins / Q000378:metabolism; D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005838:Genotype; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011743:Pyrimidines / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D000970:Antineoplastic Agents; D001549:Benzamides; D006023:Glycoproteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate